Stockwatch: The Not-As-Bad-As-Expected Opera Of Johnson & Johnson’s Q2 Earnings
What Do J&J’s Bellwether Results Tell Us About Wider Pharma Sector In 2020?
Executive Summary
With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.